14. Segment Data

Prior to the merger with Napo, the Company managed its operation as a single segment for the purposes of assessing performance and making operating decisions. The Company reorganized their segments to reflect the change in the organizational structure resulting from the merger with Napo. Post-merger with Napo, the Company manages its operations through two segments. The Company has two reportable segments-human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is approved by the U.S. FDA for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

The Company’s reportable segments net sales and net income consisted of:


	Year Ended
	December 31,
	2018		2017
Revenue from external customers
Human Health	$	4,121,913	$	1,062,920
Animal Health		294,232		3,298,266
Consolidated Totals	$	4,416,145	$	4,361,186

Segment profit (loss)
Human Health	$	(12,337,529)	$	(14,860,754)
Animal Health		(19,808,528)		(7,107,860)
Consolidated Totals	$	(32,146,057)	$	(21,968,614)

The Company’s reportable segments assets consisted of the following:


		December 31,		December 31,
	2018		2017
Segment assets
Human Health	$	37,985,935	$	41,754,603
Animal Health		54,893,593		36,807,184
Total	$	92,879,528	$	78,561,787

The reconciliation of segments assets to the consolidated assets is as follows:



	2018		2017
Total assets for reportable segments	$	92,879,528	$	78,561,787
Less: Investment in subsidiary		(29,240,965)		(29,240,965)
Less: Intercompany loan		(22,596,618)		(2,000,000)
Less: Intercompany receivable		—		(3,691,616)
Consolidated Totals	$	41,041,945	$	43,629,206